Title page

Autoimmune Thyroid Disease Correlates to Islet Autoimmunity on Zinc Transporter 8 Autoantibody

Yun Cai*, Jieni Yan*, Yong Gu, Heng Chen, Yang Chen, Xinyu Xu, Mei Zhang, Liping Yu, Xuqin Zheng △, Tao Yang △

1 Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China;
2 Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.

* These authors contributed equally to this work.
△ Corresponding author and person to whom reprint requests should be addressed:
Xuqin Zheng, E-mail: zhengxuqin@njmu.edu.cn
Tao Yang, E-mail: yangt@njmu.edu.cn

Department of Endocrinology & Metabolism, the First Affiliated Hospital of Nanjing Medical University,
300 Guangzhou Road, Nanjing, 210029, Jiangsu, China
Tel/Fax: 86-25-83781781

Running title: AITD and ZnT8A

Keywords

autoimmune thyroid disease, type 1 diabetes mellitus, zinc transporter 8 autoantibody, thyroid
peroxidase autoantibodies

*Word count: 3580*
Abstract

Objective: The most common coexisting organ-specific autoimmune disease in patients with type 1 diabetes mellitus (T1DM) is autoimmune thyroid disease (AITD). However, there have been little clinical reports based on large population about the prevalence of zinc transporter 8 autoantibody (ZnT8A) and other islet autoantibodies in AITD patients. We aimed to explore the presence of islet autoantibodies, ZnT8A, glutamic acid decarboxylase autoantibodies (GADA) and insulinoma-associated antigen 2 autoantibodies (IA-2A) compared with thyroid autoantibodies, thyroid peroxidase autoantibodies (TPOAb) and thyroglobulin autoantibodies (TGAb) and thyrotropin receptor autoantibodies (TRAb) in patients with Graves’ disease (GD), Hashimoto’s thyroiditis (HT) and T1DM patients with AITD.

Methods: Totally, 389 patients with GD, 334 patients with HT, 108 T1DM patients with AITD and 115 healthy controls (HC) were recruited in the study. Islet autoantibodies (ZnT8A, GADA and IA-2A) were detected by radioligand binding assay. Thyroid autoantibodies, TPOAb and TGAb were detected by chemiluminescence assay, and TRAb was detected by radioimmunoassay.

Results: The prevalence of ZnT8A, GADA and IA-2A was higher in GD and HT patients than that of HC (ZnT8A: GD 8.48%, HT 10.8% vs HC 1.74%; GADA: GD 7.46%, HT 7.74% vs HC 0.870%; IA-2A: GD 4.88%, HT 3.59% vs HC 0%; All P<0.05); but lower than that of T1DM subjects with AITD (ZnT8A: 42.6%; IA-2A: 44.4%; GADA: 74.1%; all P < 0.0001).

Conclusions: An increased prevalence of ZnT8A as well as GADA and IA-2A was found in both GD and HT patients, indicating that there is a potential link between thyroid autoimmunity and islet autoimmunity.
1. Introduction

Autoimmune thyroid disease (AITD) is a common organ-specific autoimmune disorder which includes two main clinical diseases: Graves’ disease (GD) and Hashimoto’s thyroiditis (HT). Both GD and HT share the immunologic manifestation of the presence of circulating autoantibodies such as thyrotropin receptor autoantibodies (TRAb), thyroid peroxidase autoantibodies (TPOAb) and thyroglobulin autoantibodies (TGAb). TRAb occur predominantly in GD and play a key role in Graves’ hyperthyroidism, while TGAb and TPOAb are more characteristic for HT, which is correlated with thyroidal damage and lymphocytic inflammation\(^1,2\).

Individuals with AITD may be associated with other autoimmune diseases, of which type 1 diabetes mellitus (T1DM) is the most frequent\(^3-5\). The phenotype is referred as Autoimmune Polyendocrine Syndrome Type II (APS II) when T1DM and AITD occur in the same individual, even sometimes coexist in the same family \(^6,7\). T1DM, as well as AITD, develops through a complex interaction of genetic and environmental risk factors which result in autoimmune destruction of the specific organs involving humoral and cellular immune responses \(^1,2,4,8,9\). Many studies have showed the prevalence rate of thyroid autoantibodies ranging from 3.7-35% in T1DM patients, some of which suggested the associations between thyroid autoantibodies and islet autoantibodies\(^10-14\). However, little work has been done about the anti-islet autoimmune status in non-diabetic patients with AITD\(^15-23\). As summarized in Supplemental Table S1, the prevalence rates of glutamic acid decarboxylase autoantibodies (GADA), islet cell autoantibodies (ICA), insulinoma-associated antigen 2 autoantibodies (IA-2A) and insulin autoantibodies (IAA) in patients with AITD were either slightly or significantly higher than those in healthy controls (HC), indicating the distinct value of studying islet immune status in AITD.

ZnT8A is the recently identified new marker of autoimmunity in diabetes \(^24\). Furthermore,
previous studies have demonstrated the presence of zinc transporter 8 autoantibody (ZnT8A) predisposes non-obese adult-onset diabetes patients to AITD\(^2\)\(^\text{5}\). However, there has been no clinical study based on large population focusing on ZnT8A in both GD and HT patients without diabetes mellitus (DM).

Our study aims to measure three islet autoantibodies, ZnT8A, GADA and IA-2A in Chinese Han patients with GD and HT (but without DM), as well as to investigate the relationship between islet autoantibodies and thyroid autoantibodies. In addition, the differences in prevalence among AITD, T1DM patients with AITD (GD or HT) and HC were compared to explore the anti-islet autoimmune status. The data gained in this analysis are supposed to provide a rationale for screening programs for active case-finding strategies in specialized centers.

2. Materials and Methods

2.1 Subjects

There were 389 Chinese patients with GD [284 female and 105 male; aged 38.9 ± 14.0 years; body mass index (BMI) 22.1 ± 3.2 kg/m\(^2\)] and 334 patients with HT (301 female and 33 male; aged 41.6 ± 14.3 years; BMI 22.7 ± 3.4 kg/m\(^2\)), who have not been diagnosed with DM before, recruited in our study. These two autoimmune thyroid diseases were diagnosed clinically by endocrinologists and confirmed by clinical symptoms and abnormal levels of thyroid hormones and autoantibodies to TRAb, TPOAb and/or TGAb, as well as ultrasound examination. 108 patients with T1DM and AITD (67 female and 41 male; aged 32.7±17.5 years; BMI 20.8 ± 3.4 kg/m2) were recruited in our study. Individuals with T1DM were diagnosed according to the diagnosis criteria of World Health Organization and American Diabetes Association. 115 healthy controls (87 female and 28 male; aged 44.7±12.8 years; BMI 21.4 ± 2.6 kg/m\(^2\)) were also included as HC groups. Sera of patients with GD or HT and
HC were obtained in the endocrinology department of the First Affiliated Hospital of Nanjing Medical University from October 2010 to September 2013, and sera of T1DM with AITD patients were obtained at 26 centers in China from June 2010 to Oct 2012. The clinical characteristics of all subjects are summarized in Table 1. Blood samples were collected for thyroid function, thyroid autoantibodies detection and further islet autoantibodies assay. However, blood samples for HLA genotyping and fasting C-peptide were not collected in solely AITD patients.

Our study was approved by the appropriate ethical committees, and informed consent was obtained from all participants.

2.2 Islet autoantibodies assay

389 GD blood samples and 334 HT blood sample taken into the plain tubes, which were drawn at the patients’ enrollment, were centrifuged at 350×g and serum was stored frozen at −80°C for 6.36 ± 6.34 months for detecting islet autoantibodies. Serum islet autoantibodies were measured by radioligand binding assay as previously described26, 27, using 35S-labeled glutamic acid decarboxylase-65 (GAD65), protein-tyrosine-phosphatase-2 (IA-2) and zinc transporter 8 (ZnT8). The plasmid containing the complementary DNA for cytoplasmic carboxy-terminal domains (amino acid 268–369) of human ZnT8 carrying 325Arg (designated as CR) or a hybrid construct of the CR and 325Trp (CW; designated as CW-CR) with a CLFCEDPCDPSTPPGSSqGGKDFSILLME hinge junction was generated.

Antibody levels were expressed as an immunoprecipitation index, which is defined as (sample – negative control)/ (positive control - negative control). The cut-off for positivity for GADA, IA-2A and ZnT8A was defined as a value above 0.048, 0.018, and 0.015 respectively, based on the 99th percentile of 102 (52 female and 50 male; aged 44.7±14.1 years; BMI 21.4 ± 2.6 kg/m^2), 315 (167 female and 148 male; aged 45.5±14.1 years; BMI
21.8 ± 2.5 kg/m²) and 218 (110 female and 108 male; aged 46.1±14.4 years; BMI 21.6 ± 2.6 kg/m²) healthy control subjects (non-diabetic individuals without known autoimmune disease and no family history of diabetes).

Our laboratory has been validated in Islet Autoantibody Standardization Program 2020 with 60.0% study sensitivity and 100% study specificity for GADA, 70.0% study sensitivity and 100% study specificity for IA-2A and 62.0% study sensitivity and 100% study specificity for ZnT8A. The coefficient of variation (CV) within-batch of measuring IA-2A, GADA, ZnT8A is 5-9%, 7-9% and 4-7% respectively, while the CV between-batch is 8-10%, 5-10% and 6-12% respectively.

2.3 Thyroid function and antithyroid antibodies

346 GD and 290 HT blood samples were collected at the study entry concurrently for detecting thyroid function and antithyroid antibodies. Free triiodothyronine (FT3), free tetraiodothyronine (FT4), thyroid-stimulating hormone (TSH), TgAb, and TPOAb were all measured by chemiluminescence assays (Roche Diagnostics GmbH, Germany), while TRAb was tested by radioimmunoassay (Cisbio Bioassays, France). Reference ranges for adults are TSH, 0.270–4.20 mU/L; FT3, 3.10–6.80 pmol/L; FT4, 12.0–22.0 pmol/L; TgAb < 115 IU/ml; TPOAb < 34.0 IU/ml; and TRAb, 0–1.50 IU/L.

2.4 Statistical analysis

Statistical analysis was performed with SPSS 19.0 for Windows and Prism 9 for Mac. Results are shown as mean ± standard deviation or proportion (%) or otherwise documented as positive cases, or odds ratio (OR), 95% confidence interval (CI). Unpaired Student’s t-test or ANOVA was used to compare groups, and Kruskal-Wallis test was used for multigroup measurement data with unequal variances. The difference between classified variables was
tested using $\chi^2$ or Fisher’s exact test if the expected number of subjects in any cell was less than five. Multiple logistic regression model was used to analyze the correlation of measurement data. Statistical significance was defined as $P<0.05$.

3. Results

3.1 Clinical characteristics of patients in GD, HT, T1DM with AITD and HC groups

The clinical baselines of GD, HT, T1DM with AITD and HC groups have been described in Table 1 and Fig.1A. Among the 346 GD patients and 290 HT patients, three thyroid autoantibodies were detected currently when blood samples collected. We observed significantly higher frequencies of either TPOAb or TGAb in the HT patients compared with the GD patients (TPOAb: 81.4% vs 73.4%; TGAb: 81.4% vs 44.8%, both $P<0.0001$), while the prevalence of TRAb was significantly higher in the GD patients compared with the HT patients (80.1% vs 10.7%, $P<0.0001$). When it comes to T1DM with AITD subjects, due to the composition of diseases (98 of 108 were diagnosed as HT), there were remarkably higher frequencies of TPOAb but lower frequencies of TGAb comparing with HT patients (TPOAb: 92.6% vs 81.4%, $P<0.01$; TGAb: 56.5% vs 81.4%, $P<0.0001$, while TRAb was similarly as HT group (10.2% vs 10.7%, $P>0.05$).

The thyroid function of patients was measured when they were recruited in this study. There were greatly differences among FT3, FT4, TSH when comparing GD patients and HT patients, which was caused by GD patients recruited were more prone to hyperthyroidism than HT patients (FT3: 13.3±11.5 vs 4.63±2.50, FT4: 33.9±26.0 vs 15.3±8.85, TSH: 2.30±10.4 vs 11.8±24.6, all $P<0.0001$).

3.2 Prevalence of islet autoantibodies in different groups

All of 389 GD patients’ and 334 HT patients’ sera were measured three islet autoantibodies. There were 71 (18.3%) GD patients and 64 (19.2%) HT patients separately
positive for at least one islet autoantibodies, both higher than that in HC group (3/115, 2.61%, both P<0.00001) (**Fig.1B, Fig.2D**). We followed those 135 islet-autoantibody-positive AITD patients up around 8.78±1.26 years according to their outpatient clinical records and found 3 patients were diagnosed as type 2 diabetes mellitus (T2DM). One patient was diagnosed T2DM at the same year but 2 months later followed by the diagnosis of HT, while one was diagnosed 5 years and the other one was diagnosed 9 years after HT. Interestingly, all of them were recruited in HT group and positive for single islet autoantibody, ZnT8A, GADA and IA-2A respectively.

The prevalence of islet autoantibodies in AITD patients (GD and HT separately) was higher than that in HC (GD vs HC : ZnT8A: 8.48% vs 1.74%, P<0.05; IA-2A: 4.88% vs 0%, P<0.05; GADA: 7.46% vs 0.870%, P<0.05; 1 islet Ab: 18.3% vs 2.61%, P<0.0001; HT vs HC : ZnT8A: 10.8% vs 1.74%, P<0.01; IA-2A: 3.59% vs 0%, P<0.05; GADA: 7.74% vs 0.870%, P<0.05; 1 islet Ab: 19.2% vs 2.61%, P<0.0001). However, there was no difference in positive rate between GD and HT patients (ZnT8A: 8.48% vs 10.8%; IA-2A: 4.88% vs 3.59%; GADA: 7.46% vs 7.74%; 1 islet Ab: 18.3% vs 19.2%; all P >0.05)(**Fig.2A,B,C,D**). Furthermore, the prevalence of at least two islet antibodies positive in GD group, which in HC was 0%, was slightly higher than HT group without significance (**Fig.2E**). In accordance with expectation, the islet autoantibodies’ frequencies of patients with both T1DM and AITD were the highest, when comparing them with GD and HT subjects(ZnT8A: 42.6%; IA-2A: 44.4%; GADA: 74.1%; 1 islet Ab: 88.0%; 2 islet Ab: 49.1%, all P < 0.0001)

### 3.3 Comparison of the prevalence of islet autoantibodies in AITD subjects with high and low titer of TPOAb

According to previous study28,29, we divided AITD patients into 2 subgroups according to the titer of TPOAb, namely high-titer TPOAb (H-TPOAb) group (≥ 100 IU/ml) and low-titer TPOAb (L-TPOAb ) group (<100 IU/ml). There were 217 H-TPOAb and 129
L-TPOAb subjects in GD group, while 197 H-TPOAb and 93 L-TPOAb subjects in HT group respectively. Considered GD and HT as a whole AITD group, we observed an increased positive rate of IA-2A in L-TPOAb AITD patient (IA-2A: 6.76% vs 3.14%, P<0.05). Moreover, the positive rate of GADA and at least 1 islet autoantibody shows no significance between L-TPOAb and H-TPOAb groups (GADA:9.01 % vs 6.28%, P>0.05; ≥1 islet Ab: 21.2% vs 17.9%, P>0.05). In contrast, the prevalence of ZnT8A in H-TPOAb group was 10.9% (45/414), compared with 8.11% (18/222, P>0.05) in L-TPOAb group (Fig.3A). There was similar trend which was observed in GD and HT groups but without significance (Supplemental Figure S1). However, the cumulative prevalence for any islet autoantibody as well as at least one islet autoantibody differed little with the titer of TPOAb increased (Fig.3B).

In addition, according to the positivity of islet autoantibodies, we divided AITD patients into 8 subgroups as presented in Supplemental Table S2. Further analyzing the level of three islet autoantibodies between subgroups, a higher prevalence for TPOAb positivity between IA-2A-negative and IA2A-positive AITD patients (72.5% vs 68.2%, P< 0.05; OR=0.4037, 95% CI: 0.2003-0.8300) was observed. Furthermore, a higher proportion of patients with high-titer TPOAb was found in the IA-2A-negative than that of IA2A-positive AITD patients (59.1% vs 35.5% P< 0.05; OR=0.3806, 95% CI: 0.1754-0.8150). There were no statistically significant differences in sexual proportion, subtypes of disease, age, duration, anti-thyroid treatment, and level of either TSH or FT4 between islet autoantibody-positive and -negative AITD patients, except for the statistically decreases in rate of BMI between IA-2A-positive and -negative AITD patients(P<0.01, β= 0.1506, standard error: 0.05790, EXP(β)=1.163, 95% CI =1.039-1.31).These findings suggested that the increasing level of islet autoimmunity was independent of subtypes of disease, gender, age, duration, anti-thyroidal treatment, TGAb positivity and thyroid function, but the BMI, as well as the positivity and titer of
TPOAb were related with IA-2A.

4. Discussion

The most common coexisting organ-specific autoimmune disease in patients with T1DM is AITD. In our study, based on a larger cohort of 723 Chinese AITD patients, the prevalence of ZnT8A was as high as 8.48% and 10.8% in GD and HT patients respectively, which was significantly higher than that in HC and lower than T1DM with AITD. It was also a novel finding that the prevalence rate of ZnT8A was much higher than that of GADA (GD:7.46%, HT: 7.74%) and IA-2A (GD:4.88%, HT: 3.59%) in AITD patients, as GADA in the previous studies was the highest diabetes-associated antibody. Even though there were only 3 patients positive for single islet antibody developing T2DM during 8.78±1.26 followed-up years, the diabetes progression may still prove the relations between islet autoimmunity and diabetes in our study. We diagnosed them based on the clinical history and treatment regimen. Despite of the fact that all of 3 patients were insulin-independent since diagnosed and without an onset by diabetic ketoacidosis (DKA) which support the diagnosis of T2DM, we still could not exclude the possibility of latent autoimmune diabetes in adults (LADA). Genetic analysis and dynamic monitoring of fasting C-peptide will be carried on in our further long-term study.

ZnT8A is the recently identified new marker of autoimmunity in diabetes. Jonsdottir et al. recruited 278 patients with newly diagnosed GD for detecting GADA, IA-2A, three variants of ZnT8A, and they observed that 7.6% of them were positive for ZnT8A at diagnosis. Rydzewska’s study, which was consisted of 44 children with GD, 65 children with HT, 199 children with T1DM with or without AITDs and 58 control children, reported the overall prevalence of ZnT8A with AITD was 9.2%, with a similar prevalence of ZnT8A in
both GD (9.1%) and HT (9.2%). Previous evidences have already shown that ZnT8A is widely distributed in a lot of endocrine or autoimmune disorders. As in the report based on 223 new-onset T1DM patients\(^\text{24}\), ZnT8A occurred in 60-80% of them, while 12 of 39 (30.9%) non-diabetic patients developed T1DM-related celiac diseases. In accord with these findings, our study illustrated the prevalence of ZnT8A in non-diabetic GD or HT patients significantly higher than that in HC but lower than T1DM with AITD patients as expected, which pointed out the perspective on ZnT8A’s representativeness in endocrine autoimmune diseases. Rydzewska et al.\(^\text{23}\) found that the strong ZnT8 expression could been observed in almost all of the thyroid follicular cells and some of the cytoplasm and the perinuclear area of the hyperplastic C cells. In keeping with that, ZnT8 was identified as a major autoantigen in T1DM and localized in insulin secretory granules \(^\text{24, 31}\), which expressed in other secretory cell types of murine like pancreatic \(\alpha\) islet cells, thyroid cubical cells and adrenal gland cortex cells as well \(^\text{32}\). Our data further confirmed the widespread role of ZnT8 in the endocrine system mentioned above\(^\text{22, 24, 32}\).

GADA and IA-2A are recommended markers for suspected diagnosis of T1DM or for the prediction of T1DM in research settings\(^\text{33}\). Consistent with previous studies\(^\text{17, 19, 20, 34, 35}\), our study demonstrated the prevalence of GADA and IA-2A was ranging from 7-8% and 3-5% respectively in AITD patients. A recent Chinese study, in which 190 T1DM and 135 LADA patients participated, revealed that high level of GADA could be a strong predictor of the development of thyroid autoimmunity in patients with autoimmune diabetes \(^\text{36}\), as well as the finding of Lethagen et al.\(^\text{37}\) demonstrated that GADA positivity could be a marker of subclinical insulitis in a study on 441 non-diabetic patients with autoimmune thyroiditis. Both of the studies indicated the potential of GADA in predicting concurrent of thyroid autoimmunity and islet autoimmunity. Additionally, Pilia’s study\(^\text{19}\) illustrated that IA-2A was significantly prevalent in 236 non-obese Sardinian children with autoimmune
thyroiditis, which is consistent with our results to some degree, however, their prevalence of GADA showed no significant differences compared with HC. The composition of patients and differences of race may explain the discordance with our results.

According to the titer of TPOAb, we compared the prevalence of ZnT8A, GADA and IA-2A in H-TPOAb and L-TPOAb groups. Only a higher positive rate of IA-2A (P<0.05, OR =0.4474, 95% CI = 0.2170–0.9709) was observed in L-TPOAb patients. Similarly, the positive rate of GADA seemed higher in L-TPOAb group (P>0.05, OR = 0.6768, 95% CI = 0.3645 - 1.252). In contrast, ZnT8A positivity was higher in H-TPOAb group but without significance (P>0.05, OR = 1.382, 95% CI = 0.7976–2.480). Therefore, we infer that AITD patients with H-TPOAb are more likely to develop ZnT8A positivity, meanwhile patients with L-TPOAb develop GADA and IA-2A. Moreover, despite the positive rate of ZnT8A, GADA or IA-2A did not vary much with TPOAb titer increasing, we still could observe the increasing trend along with the TPOAb titer rising. Rogowicz-Frontczak et al.\textsuperscript{25} revealed an association among positive ZnT8A, GADA and positive titer of TPOAb in his study consisted of 80 non-obese adults diagnosed as LADA, and Jonsdottir et al.\textsuperscript{11} also demonstrated an association between two thyroid autoantibodies (TPOAb and TGAb) and ZnT8A or GADA positivity in a cohort of 2433 newly diagnosed T1DM children. Unfortunately, no statistical differences were exhibited in the prevalence of ZnT8A and GADA comparing high and low-TPOAb titre in our study, longitudinal studies based on larger follow-up population are necessary in the future to determine the predict value of both GADA and ZnT8A. Interestingly, the significant differences of TPOAb-positive proportion as well as H-TPOAb proportion between IA-2A negative and positive patients (both P<0.05), further indicating the relations between IA-2A and TPOAb titers.

Our study is powered by large number of GD, HT, T1DM with AITD and HC patients of whom thyroid autoantibodies and islet autoantibodies were detected. However, we still
acknowledge the limitations. First of all, our previous study of 600 Chinese T1DM patients showed the positive rates of ZnT8A in patients carried DRB1*0901, IA2A in patients carried DRB1*0405 and A*1101-DRB1*0901 and GADA in patients carried DRB1*0901 and A*2402-DRB1*0901 were significantly higher than those not carried. HLA genotyping and association between HLA haplotype and islet autoantibodies should be continued in our future research. Secondly, lack of dynamic monitoring of patients C-peptide and blood glucose metabolic index limited the observation on the changes of islet \( \beta \) cell function and anti-islet autoimmune status. Thirdly, the discordance of sexual and age proportion among patients in different groups which may decrease the statistical power, we should further expand the subjects’ population to avoid it in the future long-term cohort. Last but not least, some recent studies have shown that patients with AITD are at increased risk of developing T1DM, however, the presence of any one single autoantibody appeared not to be predictive for the disease. Unfortunately, there were only 3 out of 135 patients who were positive for single islet autoantibody developed diabetes and clinically diagnosed as T2DM. Research on investigating the potential relations between islet autoantibody and special types of diabetes (such as LADA) should be launched in the future.

5. Conclusions

In conclusion, an increased prevalence of ZnT8A as well as high prevalence of islet autoimmunity was found in both GD and HT patients. It indicates there is a potential link between thyroid autoimmunity and islet autoimmunity. We suggest, therefore, patients with AITD may need screening for islet autoantibodies, and those who positive for at least one islet autoantibodies need long-term follow-up for islet function and blood glucose.

Declarations
Ethics approval and consent to participate

The experimental protocol has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and conformed to the provisions of the Declaration of Helsinki (Ethical approval No. 2010-SR-021).

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest Statement

The authors declare that they have no competing interests.

Funding

This work is supported by the grant from the National Natural Science Foundation of China (No.81270897), the Jiangsu Provincial Special Program of Medical Science (BL2012026) and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Authors' contributions

C.Y. and Y.J.N designed and wrote the manuscript and performed most experiments. Y.T. and Z.X.Q. contributed to design of the study and reviewed and edited the manuscript. Y.L.P. help to take control of the autoantibodies assay. All authors reviewed and take full responsibility for the contents of the manuscript. Y.T is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements

We express our sincere appreciation to George Eisenbarth, John Hutton and Howard Davidson (Barbara Davis Center of Childhood Diabetes, University of Colorado, CO, USA)
for their tutoring and guidance.

References

1. Weetman AP. Graves' disease. N Engl J Med. Oct 26 2000;343(17):1236-48. doi:10.1056/NEJM200010263431707
2. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. The New England journal of medicine. 2003;348(26):2646-2655.
3. Golden B, Levin L, Ban Y, Concepcion E, Greenberg DA, Tomer Y. Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for common and unique genes. J Clin Endocrinol Metab. 2005;90(8):4904-4911.
4. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F, Hoffenborg E, Nelson JC, Gottlieb PA, Rewers M, et al. Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005;28(4):850-855.
5. De Block CE, De Leeuw IH, Vertommen JJ, Rooman RP, Du Caju MV, Van Campenhout CM, Weyler JJ, Winnock F, Van Autreve J, Gorus FK. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. Clin Exp Immunol. 2001;126(2):236-241.
6. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. The New England journal of medicine. 2004;350(20):2068-2079.
7. Jenkins RC, Weetman AP. Disease associations with autoimmune thyroid disease. Thyroid. 2002;12(11):977-988.
8. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. The New England journal of medicine. 1986;314(21):1360-1368.
9. Brorsson CA, Pociot F. Shared Genetic Basis for Type 1 Diabetes, Islet Autoantibodies, and Autoantibodies Associated With Other Immune-Mediated Diseases in Families With Type 1 Diabetes. Diabetes Care. 2015;38 Suppl 2:S8-13. doi:10.2337/dcs15-2003
10. Holl RW, Bohm B, Loos U, Grabert M, Heinze E, Homoki J. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender, and HLA type. Horm Res. 1999;52(3):113-118.
11. Jonsdottir B, Andersson C, Carlsson A, Delli A, Forsander G, Ludvigsson J, Marcus C, Samuelsson U, Ortvist E, Lernmark A, et al. Thyroid autoimmunity in relation to islet autoantibodies and HLA-DQ genotype in newly diagnosed type 1 diabetes in children and adolescents. Diabetologia. 2013;56(8):1735-1742. doi:10.1007/s00125-013-2934-9
12. Hanukoglu A, Mizrachi A, Dalal I, Admoni O, Rakover Y, Bistritzer Z, Levine A, Somekh E, Lehmann D, Tuval M, et al. Extrapancreatic autoimmune manifestations in type 1 diabetes patients and their first-degree relatives: a multicenter study. Diabetes Care. 2003;26(4):1235-1240.
13. Jaeger C, Hatziagelaki E, Petzoldt R, Brezgel RG. Comparative analysis of organ-specific autoantibodies and celiac disease–associated antibodies in type 1 diabetic patients, their first-degree relatives, and healthy control subjects. Diabetes Care. 2001;24(1):27-32.
14. Bonifacio E, Mayr A, Knopff A, Ziegler AG. Endocrine autoimmunity in families with type 1 diabetes: frequent appearance of thyroid autoimmunity during late childhood and adolescence. Diabetologia. 2009;52(2):185-192. doi:10.1007/s00125-008-1206-6
15. Ng WY, Thai AC, Lui KF, Yeo PP, Cheah JS. IgG-class insulin autoantibodies in autoimmune thyroid disease. Int Arch Allergy Appl Immunol. 1990;91(4):431-436.
16. Yamaguchi Y, Chikuba N, Ueda Y, Yamamoto H, Yamasaki H, Kalashnikova T, Akazawa S, Nagataki S. Islet cell antibodies in patients with autoimmune thyroid disease. Diabetes. 1991;40(3):319-322.
17. Kawasaki E, Abiru N, Yano M, Uotani S, Matsumoto K, Matsuo H, Yamasaki H, Yamamoto H, Yamaguchi Y, Akazawa S. Autoantibodies to glutamic acid decarboxylase in patients with autoimmune thyroid disease: relation to competitive insulin autoantibodies. J Autoimmun. 1995;8(5):633-643.
18. Maugendre D, Vérité F, Guilhem I, Genetet B, Allamoc H, Delamare M. Anti-pancreatic autoimmunity and Graves' disease: study of a cohort of 600 Caucasian patients. European journal of endocrinology. 1997;137(5):503-510.
19. Pilia S, Casini MR, Cambuli VM, Ibbia A, Civolani P, Zavattari P, Incarni M, Mossa P, Baroni MG, Mariotti S, et al. Prevalence of Type 1 diabetes autoantibodies (GAD and IA2) in Sardinian children and adolescents with autoimmune thyroiditis. Diabet Med. 2011;28(8):896-899. doi:10.1111/j.1464-5491.2011.03313.x
20. Moriguchi M, Nosu S, Kawabata Y, Yamauchi T, Harada T, Komaki K, Babaya N, Hiromine Y, Ito H, Yamagata S, et al. Clinical and genetic characteristics of patients with autoimmune thyroid disease with anti-islet autoimmunity. *Metab Clin Exp.* 2011;60(6):761-766. doi:10.1016/j.metabol.2010.07.025

21. Sallorenzo C, Silva R, Kasamatsu T, Dib S. Prevalence of pancreatic autoantibodies in non-diabetic patients with autoimmune thyroid disease and its relation to insulin secretion and glucose tolerance. *Arch Endocrinol Metabol.* 2017;61(4):361-366. doi:10.1590/2359-3997000000280

22. Jonsdottir B, Jönsson I, Lantz M. Prevalence of diabetes and presence of autoantibodies against zinc transporter 8 and glutamic decarboxylase at diagnosis and at follow up of Graves' disease. *Endocrine.* 2019;64(1):48-54. doi:10.1007/s12020-019-01852-w

23. Rydzewska M, Michalak J, Bossowska A, Chen S, Black S, Powell M, Furmaniak J, Rees Smith B, Bossowski A. Analysis of diabetes-associated autoantibodies in children and adolescents with autoimmune thyroid diseases. *J Pediatr Endocrinol Metabol.* 2019;32(4):355-361. doi:10.1515/jpem-2018-0367

24. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. *Proc Natl Acad Sci USA.* 2007;104(43):17040-17045.

25. Rogowicz-Frontczak A, Zozulilska-Ziołkiewicz D, Litwinowicz M, Niedźwiecki P, Wyka K, Wierusz-Wysocka B. Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes? *European journal of endocrinology.* 2014;170(4):651-658. doi:10.1530/EJE-13-0901

26. Gu Y, Zhang M, Chen H, Wang Z, Xing C, Yang H, Xu X, Liu Y, Zhou Z, Yu L, et al. Discordant association of islet autoantibodies with high-risk HLA genes in Chinese type 1 diabetes. *Diabetes Metab Res Rev.* 2011;27(8):899-905. doi:10.1002/dmrr.1270

27. Liu J, Bian L, Ji L, Chen Y, Chen H, Gu Y, Ma B, Gu W, Xu X, Shi Y, et al. The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients. *Science China Life sciences.* 2016;59(9):930-9. doi:10.1007/s11427-016-5052-3

28. Paparodis RD, Bantouna D, Karvounis E, Imam S, Jaume JC. Higher TSH Is Not Associated With Thyroid Cancer Risk in the Presence of Thyroid Autoimmunity. *J Clin Endocrinol Metab.* 2020;105(7):doi:10.1210/clinem/dgaad237

29. Imam S, Dar P, Paparodis R, Almotah A, Al-Khudhair A, Hasan SA-M, Salim N, Jaume JC. Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer. *Endocrine.* 2020;105(7):doi:10.1016/j.metabol.2010.07.025

30. Pietropaolo M, Peakman M, Pietropaolo SL, Zanone MM, Foley TP, Becker DJ, Trucco M. Combined analysis of GAD65 and ICA512(IA-2) autoantibodies in organ and non-organ-specific autoimmune diseases confirms high specificity for insulin-dependent diabetes mellitus. *J Autoimmun.* 1998;11(1)

31. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. *Diabetes.* 2004;53(9):2330-2337.

32. Murgia C, Devirgiliis C, Mancini E, Donadel G, Zalewski P, Perozzi G. Diabetes-linked zinc transporter ZnT8 is a homodimeric protein expressed by distinct rodent endocrine cell types in the pancreas and other glands. *Nutr Metab Cardiovasc Dis.* 2009;19(6):431-439. doi:10.1016/j.numecd.2008.09.004

33. Winter WE, Schatz DA. Autoimmune markers in diabetes. *Clin Chem.* 2011;57(2):168-175. doi:10.1373/clinchem.2010.148205

34. Primo ME, Niepmniszcze H, Poskus E, Sala MS, Guaita SS, Sica MP, Villalba A, Cardoso A, Bruno OD. Frequency of pancreatic beta-cell autoimmunity markers in patients with autoimmune thyroid disease. *Medicina (B Aires).* 2008;68(1):37-42.

35. Jonsdottir B, Larsson C, Carlsson A, Forsander G, Ivarsson SA, Lemmark Å, Ludvigsson J, Marcus C, Samuelsson U, Ortvqvist E, et al. Thyroid and Islet Autoantibodies Predict Autoimmune Thyroid Disease at Type 1 Diabetes Diagnosis. *J Clin Endocrinol Metab.* 2017;102(4):1277-1285. doi:10.1210/jc.2016-2335

36. Jin P, Huang G, Lin J, Yang L, Xiang B, Zhou W, Zhou Z. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults. *Clin Endocrinol (Oxf).* 2011;74(5):587-592. doi:10.1111/j.1365-2265.2011.03976.x

37. Lethagen AL, Ericsson UB, Hallengren B, Groop L, Tuomi T. Glutamic acid decarboxylase antibody positivity is associated with an impaired insulin response to glucose and arginine in nondiabetic patients with autoimmune thyroiditis. *J Clin Endocrinol Metab.* 2002;87(3):1177-1183.

38. Taniyama M, Kasuga A, Nagayama C, Ito K. Occurrence of type 1 diabetes in graves’ disease patients who are positive for antiglutamic Acid decarboxylase antibodies: an 8-year followup study. *J Thyroid Res.* 2010;2011:306487. doi:10.4061/2011/306487

39. Gorus FK, Goubert P, Semakula C, Vandewalle CL, De Schepper J, Scheen A, Christie MR, Pipeleers DG. IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict diabetes in their siblings. *The Belgian Diabetes Registry. Diabetologia.* 1997;40(1):95-99.
40. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. *Diabetes*. 1997;46(11):1701-1710.

41. Schlosser M, Strebelow M, Wassmuth R, Arnold M-L, Breunig I, Rjasanowski I, Ziegler B, Ziegler M. The Karlsburg type 1 diabetes risk study of a normal schoolchild population: association of beta-cell autoantibodies and human leukocyte antigen-DQB1 alleles in antibody-positive individuals. *J Clin Endocrinol Metab*. 2002;87(5):2254-2261.
Figure 1. Frequency of islet autoantibodies and thyroid autoantibodies in Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) patients. (A) Frequency of thyroid autoantibodies is shown in 346 patients with GD (left) and 290 patients with HT (right). Of these, 323 (93.4%) and 281 (96.9%) were respectively positive for at least one thyroid autoantibody.

(B) Frequency of islet autoantibodies is shown in 389 patients with GD (left) and 334 patients with HT (right). Of these, 71 (18.3%) and 64 (19.2%) were respectively positive for at least one islet autoantibody.

Figure 2. Frequency of islet autoantibodies in type 1 diabetes mellitus with autoimmune thyroid diseases (T1DM with AITD), Graves’ disease (GD), Hashimoto’s thyroiditis (HT) and healthy controls (HC) subjects. Patients’ serum was used for measuring (A)ZnT8A, (B) IA-2A, (C) GADA by radioligand binding assay. The figures show the frequency of (A)ZnT8A, (B) IA-2A, (C) GADA, (D) at least one islet autoantibody and (E) at least two islet autoantibodies in T1DM with AITD, GD, HT and HC groups.

Figure 3. Frequency of islet autoantibodies in autoimmune thyroid diseases (AITD) (including Graves’ disease, Hashimoto’s thyroiditis) subjects with high titer TPOAb and low titer TPOAb. According to TPOAb ≥ 100 IU/ml and <100 IU/ml, we divided the AITD (containing GD and HT) into high titer...
TPOAb (H-TPOAb) and low titer TPOAb (L-TPOAb) groups separately. (A) shows the positive rate of ZnT8A (H-TPOAb vs L-TPOAb: 10.9% vs 8.11%), IA-2A (3.14% vs 6.76%), GADA (6.28% vs 9.01%) and at least one islet autoantibody (17.9% vs 21.2%) in H-TPOAb and L-TPOAb groups. (B) shows the cumulative positive rates of ZnT8A, IA-2A, GADA and at least one islet autoantibody inAITD subjects with different TPOAb titers.

\textbf{Supplemental Figure S1. Frequency of islet autoantibodies in Graves’ disease (GD), Hashimoto’s thyroiditis (HT) subjects with high titer TPOAb and low titer TPOAb.} According to TPOAb \( \geq 100 \) IU/ml and <100 IU/ml, we divided the GD and HT into high titer TPOAb (H-TPOAb) and low titer TPOAb (L-TPOAb) groups separately. Figures present the positive rate of ZnT8A, IA-2A, GADA and at least one islet autoantibody in H- TPOAb and L-TPOAb groups in (A)GD and (B)HT.

\begin{itemize}
\item \textbf{a}: \( P>0.05 \), Odds ratio = 1.029, 95% confidence interval = 0.4877-2.237
\item \textbf{b}: \( P>0.05 \), Odds ratio = 0.5104, 95% confidence interval = 0.1945-1.263
\item \textbf{c}: \( P>0.05 \), Odds ratio = 0.5705, 95% confidence interval = 0.2418-1.350
\item \textbf{d}: \( P>0.05 \), Odds ratio = 0.6937, 95% confidence interval = 0.3986-1.184
\item \textbf{e}: \( P>0.05 \), Odds ratio = 1.868, 95% confidence interval = 0.8088-4.473
\end{itemize}
f: P>0.05, Odds ratio =0.4215, 95\% confidence interval = 0.1424-1.484

g: P>0.05, Odds ratio = 0.8128, 95\% confidence interval = 0.3263-1.944

h: P>0.05, Odds ratio =0.9614, 95\% confidence interval = 0.5245-1.753
Figure 1. Frequency of islet autoantibodies and thyroid autoantibodies in Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) patients. (A) Frequency of thyroid autoantibodies is shown in 346 patients with GD (left) and 290 patients with HT (right). Of these, 323 (93.4%) and 281 (96.9%) were respectively positive for at least one thyroid autoantibody.

(B) Frequency of islet autoantibodies is shown in 389 patients with GD (left) and 334 patients with HT (right). Of these, 71 (18.3%) and 64 (19.2%) were respectively positive for at least one islet autoantibody.
Figure 1. Frequency of islet autoantibodies and thyroid autoantibodies in Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) patients. (A) Frequency of thyroid autoantibodies is shown in 346 patients with GD (left) and 290 patients with HT (right). Of these, 323 (93.4%) and 281 (96.9%) were respectively positive for at least one thyroid autoantibody.

(B) Frequency of islet autoantibodies is shown in 389 patients with GD (left) and 334 patients with HT (right). Of these, 71 (18.3%) and 64 (19.2%) were respectively positive for at least one islet autoantibody.
Figure 2. Frequency of islet autoantibodies in type 1 diabetes mellitus with autoimmune thyroid diseases (T1DM with AITD), Graves’ disease (GD), Hashimoto’s thyroiditis (HT) and healthy controls (HC) subjects. Patients’ serum was used for measuring (A) ZnT8A, (B) IA-2A, (C) GADA by radioligand binding assay. The figures show the frequency of (A) ZnT8A, (B) IA-2A, (C) GADA, (D) at least one islet autoantibody and (E) at least two islet autoantibodies in T1DM with AITD, GD, HT and HC groups.

292x182mm (144 x 144 DPI)
Figure 3. Frequency of islet autoantibodies in autoimmune thyroid diseases (AITD) (including Graves’ disease, Hashimoto’s thyroiditis) subjects with high titer TPOAb and low titer TPOAb. According to TPOAb ≥100 IU/ml and <100 IU/ml, we divided the AITD (containing GD and HT) into high titer TPOAb (H-TPOAb) and low titer TPOAb (L-TPOAb) groups separately. (A) shows the positive rate of ZnT8A (H-TPOAb vs L-TPOAb: 10.9% vs 8.11%), IA-2A (3.14% vs 6.76%), GADA (6.28% vs 9.01%) and at least one islet autoantibody (17.9% vs 21.2%) in H-TPOAb and L-TPOAb groups. (B) shows the trend of positive rate of ZnT8A, IA-2A, GADA and at least one islet autoantibody along with the TPOAb titers rising.

- a: P=0.33, Odds ratio = 1.382, 95% confidence interval = 0.7976–2.480
- b: P=0.03, Odds ratio = 0.4474, 95% confidence interval = 0.2170–0.9709
- c: P=0.20, Odds ratio = 0.6768, 95% confidence interval = 0.3645–1.252
- d: P=0.34, Odds ratio = 0.8104, 95% confidence interval = 0.5412–1.216
Table 1. Clinical characteristics of Graves’ disease (GD), Hashimoto’s thyroiditis (HT), type 1 diabetes mellitus with autoimmune thyroid diseases (T1DM with AITD), and healthy controls (HC) subjects.

| Groups          | P Value | P Value | P Value | P Value | P Value | P Value |
|-----------------|---------|---------|---------|---------|---------|---------|
| GD (n=389)      |         |         |         |         |         |         |
| HT (n=334)      |         |         |         |         |         |         |
| T1DM with AITD (n=108) |         |         |         |         |         |         |
| HC (n=115)      |         |         |         |         |         |         |
| **Gender**      |         |         |         |         |         |         |
| (female/male)   | 284/105 | 301/33  | 67/41   | 87/28   | <0.0001*| <0.05*  | <0.0001*| <0.0001*| >0.05*  | <0.0001*|
| **Age** (years) | 38.9±14.0 | 41.6±14.3 | 32.7±17.5 | 44.7±12.8 | <0.0001† | >0.05§  | <0.05§  | <0.05§  | >0.05§  | <0.0001§|
| **Duration** (years) | 3.02±5.30 | 2.04±4.11 | 1.79±4.09a | -      | <0.01†  | <0.05§  | <0.05§  | >0.05§  |  -      |  -      |
| **BMI** (Kg/m²) | 22.1±3.2 | 22.7±3.4 | 20.8±3.4 | 21.4±2.6 | <0.000‡ | >0.05§  | <0.01§  | <0.000§ | >0.01§  | <0.01§  |
| **TPOAb+** n (%) | 254/346 | 236/290 | 100/108 | -       | <0.0001* | <0.0001* | <0.0001* | <0.01*  | -       | -       |
| **TGAb+** n (%) | 155/346 | 236/290 | 61/108  | -       | <0.0001* | <0.0001* | <0.05*  | <0.0001* | -       | -       |

Copyright © 2019 the authors
| Groups | GD (n=389) | HT (n=334) | T1DM with AITD (n=108) | HC (n=115) | P | P<sub>a</sub> | P<sub>b</sub> | P<sub>c</sub> | P<sub>d</sub> | P<sub>e</sub> |
|--------|------------|------------|------------------------|------------|---|-----------|-----------|-----------|-----------|-----------|
| TRAb+  | 277/346 (80.1%) | 31/290 (10.7%) | 11/108 (10.2%) | - | <0.0001* | <0.0001* | <0.0001* | >0.05* | - | - |
| FT3 (pmol/L) | 13.3±11.5 | 4.63±2.50 | 5.37±4.28 | - | <0.0001‡ | <0.0001§ | <0.0001§ | >0.05§ | - | - |
| FT4 (pmol/L) | 33.9±26.0 | 15.3±8.85 | 20.9±14.0 | - | <0.0001‡ | <0.0001§ | <0.0001§ | <0.05§ | - | - |
| TSH (mIU/L) | 2.30±10.4 | 11.8±24.6 | 4.84±8.80 | - | <0.0001‡ | <0.0001§ | >0.05§ | <0.01§ | - | - |

P<sub>a</sub>: GD vs HT, P<sub>b</sub>: GD vs T1DM with AITD, P<sub>c</sub>: HT vs T1DM with AITD, P<sub>d</sub>: GD vs HC, P<sub>e</sub>: HT vs HC, *χ² analysis, † ANOVA, ‡ Kruskal-Wallis test, § independent-samples T Test, a represents the duration when T1DM and AITD co-exist.
Supplemental Table S1 The published studies investigated prevalence of islet autoantibodies in autoimmune thyroid diseases (AITD) patients.

| Study  | Year | Ref. | Study population                                                                 | GADA (AITD/controls)(%) | ICA (AITD/controls)(%) | IA2A (AITD/controls)(%) | IAA (AITD/controls)(%) | ZnT8A (AITD/controls)(%) |
|--------|------|------|-----------------------------------------------------------------------------------|-------------------------|------------------------|-------------------------|------------------------|--------------------------|
| Ng     | 1990 | 15   | 97 non-diabetic AITD patients                                                      | -                       | 0                      | -                       | -                      | 7.2                      |
| Yamaguchi | 1991 | 16   | 316 AITD patients (T1DM included); 53 T1DM patients; 144 healthy control subjects | 7.6/0.7                 |                        |                         |                        |                          |
| Kawasaki | 1995 | 17   | 288 non-diabetic AITD patients; 235 controls                                       | 6.3/0.9                 | 0/0                    | -                       | -                      | 3.8/0                    |
| Maugendre | 1997 | 18   | 600 Caucasian patients with recently diagnosed Graves’ disease (10 diabetics and 590 non-diabetics) | 4.9 (non-diabetic)      |                        |                         |                        |                          |
| Pilia   | 2011 | 19   | 236 non-diabetic Sardinian children and adolescents with autoimmune thyroiditis; 949 healthy controls | 5.09/3.79               | -                      | 3.39/1.16               | -                      |                          |
| Moriguchi | 2011 | 20   | 866 Japanese AITD patients (diabetics included); 282 controls                     | 5.8/2.1                 | -                      | -                       | -                      |                          |
| Author          | Year | Sample Description                                                                 | ZnT8A | GADA | IA-2A | ICA | GD   | HT    | T1DM | AITD |
|-----------------|------|-------------------------------------------------------------------------------------|-------|------|-------|-----|------|-------|------|------|
| Sallorenzo      | 2017 | 324 AITD patients (non-diabetic patients); 93 healthy controls                       | 4.9/0 | -    | -     | 0.7/0 | -    | -    | -    | -    |
| Jonsdottir      | 2019 | 278 patients with newly diagnosed GD                                                | 8.7   | 3.2  | 7.6   | 44 children with GD; 65 children with HT; 199 children with T1DM or AITD; 58 children with GD | 5.5/0 | 3.7/0 | 7.6  |
| Rydzewska       | 2019 | 23 children with T1DM or AITD                                                      | 7.3/3.4 | 5.5/0 | 3.7/0 | 9.2/3.4 |

ZnT8A, Zinc Transporter 8 Autoantibodies; GADA, Glutamic Acid Decarboxylase Autoantibody; IA-2A, Protein Tyrosine Phosphatase-2 Autoantibody; ICA, islet cell autoantibodies; GD Graves’ Disease; HT, Hashimoto’s Thyroiditis; T1DM, Type 1 Diabetes Mellitus.
Supplemental Table S2. Clinical characteristics of subgroups of autoimmune thyroid diseases subjects according to the presence of islet antibodies.

| Subgroup                  | ZnT8A+ (n=69) | ZnT8A- (n=654) | GADA+ (n=53) | GADA- (n=670) | IA-2A+ (n=31) | IA-2A- (n=692) | Islet Ab+ (n=135) | Islet Ab- (n=588) | P Value |
|---------------------------|---------------|----------------|--------------|--------------|--------------|---------------|-------------------|-------------------|---------|
| Sex(female/male)          | 61/8          | 524/130        | 44/9         | 541/129      | 27/4         | 558/134       | 113/22            | 472/116           | >0.05*  |
| Disease (GD/HT)           | 33/36         | 356/298        | 28/25        | 360/310      | 19/12        | 350/342       | 71/64             | 319/269           | >0.05*  |
| Age (years)               | 40.1          | 40.3           | 39.2         | 40.4         | 41.7         | 40.2          | 39.6              | 40.5              | >0.05†  |
| Duration (years)          | 3.30±5.60     | 2.51±4.74      | 2.44±4.36    | 2.59±4.86    | 2.88±4.09    | 2.56±4.85     | 2.83±4.66         | 2.51±4.85         | >0.05†  |
| BMI (Kg/m²)               | 21.8±2.9      | 22.4±3.4       | 22.9±4.1     | 22.3±3.3     | 20.8±2.2     | 22.5±3.4      | 22.2±3.3          | 22.4±3.3          | >0.05†  |
| TPOAb+ (n%)               | 53 (76.8%)    | 465 (71.1%)    | 32 (60.3%)   | 486 (72.5%)  | 16 (51.6%)   | 502 (72.5%)   | 90 (68.2%)        | 428 (72.8%)       | >0.05*  |
| High-titer                | 46 (66.7%)    | 374 (57.2%)    | 25 (47.2%)   | 395 (59.0%)  | 11 (35.5%)   | 409 (59.1%)   | 76 (56.3%)        | 344 (58.5%)       | >0.05*  |

* indicates statistically significant difference (p < 0.05)
| Subgroup  | ZnT8A+ (n=69) | ZnT8A- (n=654) | GADA+ (n=53) | GADA- (n=670) | IA-2A+ (n=31) | IA-2A- (n=692) | Islet Ab+ (n=135) | Islet Ab- (n=588) | P Value |
|-----------|--------------|----------------|-------------|---------------|---------------|---------------|----------------|-------------------|---------|
| TGAb+     |              |                |             |               |               |               |                 |                   |         |
|           | 47 (68.1%)   | 369 (56.4%)    | 30 (43.5%)  | 386 (57.6%)   | 16 (51.6%)    | 400 (57.8%)   | 81 (60.0%)      | 335                | >0.05*  |
| TRAb+     |              |                |             |               |               |               |                 |                   |         |
|           | 27 (39.1%)   | 287 (43.9%)    | 23 (43.4%)  | 291 (43.4%)   | 18 (58.1%)    | 296 (42.8%)   | 59 (43.7%)      | 258                | >0.05*  |
| Drug      |              |                |             |               |               |               |                 |                   |         |
|           | 48 (69.6%)   | 432 (66.0%)    | 28 (52.8%)  | 452 (67.5%)   | 22 (71.0%)    | 458 (66.2%)   | 91 (67.4%)      | 389                | >0.05*  |
| >22 miu/l |              |                |             |               |               |               |                 |                   |         |
| <12 miu/l |              |                |             |               |               |               |                 |                   |         |
| >4.2 pmol/l|              |                |             |               |               |               |                 |                   |         |
| TSH       |              |                |             |               |               |               |                 |                   |         |
| <0.27 pmol/l|              |                |             |               |               |               |                 |                   |         |

* Copyright © 2019 the authors

Downloaded from Bioscientifica.com at 04/30/2021 02:25:23AM via free access
Pa, ZnT8A+ vs ZnT8A-; Pb, GADA+ vs GADA-; Pc, IA-2A+ vs IA-2A-; Pd, Islet Ab+ vs Islet Ab-. ZnT8A+, ZnT8A positive; ZnT8A-, ZnT8A negative; GADA+, GADA positive; GADA-, GADA negative; IA-2A+, IA2A positive; IA-2A-, IA2A negative; Islet Ab+, at least one islet autoantibody positive; Islet Ab-, all islet autoantibodies negative. *χ² analysis, †ANOVA, ‡multiple logistic regression

a: P<0.01, β= 0.1506, standard error: 0.05790, EXP(β)=1.163, 95% confidence interval =1.039-1.31

b: P<0.05, Odds ratio =0.4037, 95% confidence interval = 0.2003-0.8300

c: P<0.05, Odds ratio =0.3806, 95% confidence interval = 0.1754-0.8150

FT3, Free triiodothyronine; FT4, free tetraiodothyronine; TSH, thyroid-stimulating hormone; TGAb, thyroglobulin autoantibodies; TPOAb, thyroid peroxidase autoantibodies; TRAb, thyrotropin receptor autoantibodies; GD Graves’ Disease; HT, Hashimoto’s Thyroiditis; BMI, Body Mass Index; T2DM, Type 2 Diabetes Mellitus; ZnT8A, Zinc Transporter 8 Autoantibodies; GADA, Glutamic Acid Decarboxylase Autoantibody; IA-2A, Protein Tyrosine Phosphatase-2 Autoantibody; BMI, body mass index.
Supplemental Figure S1. Frequency of islet autoantibodies in Graves’ disease (GD), Hashimoto’s thyroiditis (HT) subjects with high titer TPOAb and low titer TPOAb. According to TPOAb≥100 IU/ml and <100 IU/ml, we divided the GD and HT into high titer TPOAb (H-TPOAb) and low titer TPOAb (L-TPOAb) groups separately. Figures present the positive rate of ZnT8A, IA-2A, GADA and at least one islet autoantibody in H-TPOAb and L-TPOAb groups in (A)GD and (B)HT.

- a: P>0.05, Odds ratio =1.029, 95% confidence interval = 0.4877-2.237
- b: P>0.05, Odds ratio =0.5104, 95% confidence interval = 0.1945-1.263
- c: P>0.05, Odds ratio = 0.5705, 95% confidence interval = 0.2418-1.350
- d: P>0.05, Odds ratio =0.6937, 95% confidence interval = 0.3986-1.184
- e: P>0.05, Odds ratio = 1.868, 95% confidence interval = 0.8088-4.473
- f: P>0.05, Odds ratio =0.4215, 95% confidence interval = 0.1424-1.484
- g: P>0.05, Odds ratio = 0.8128, 95% confidence interval = 0.3263-1.944
- h: P>0.05, Odds ratio =0.9614, 95% confidence interval = 0.5245-1.753